In order to achieve tumor-specific targeting of adeno-associated virus (AAV)-mediated gene expression, the promoter of the glucose transporter isoform 1 (GLUT1) gene was cloned upstream of the enhanced green fluorescence protein (EGFP) and the herpes simplex virus thymidine kinase (HSVtk) gene. FACS analysis performed at 48 h after transient infection with rAAV/cytomegalovirus (CMV)egfp viral particles revealed an increase of fluorescence in all the cell lines tested. However, EGFP expression under control of the GLUT1 promoter element (rAAV/GTI-1.3egfp) was limited to the tumor cells and oncogene-transformed cells. Evidence for phosphorylation of the HSVtk substrates ganciclovir (GCV) and 125 I-deoxycytidine was found in all transfected tumor cell lines compared to noninfected controls (HCT116: 111%; MH3924A: 130%; HaCaT-RT3: 257% increase), but not in HaCaT and HUVEC cells. Furthermore, tumor cells and the oncogene-transformed (ras) cell line HaCaT-RT3 showed a GCV-induced reduction in cell number (HCT116: À71%; MH3924A: À43% and HaCaT-RT3: À31%). No statistically relevant cytotoxic effect was observed in HaCaT (6% decrease) and HUVEC cells (2% decrease). Furthermore, a reduction of 3 H-thymidine incorporation into the DNA was seen after treatment with GCV (HCT116: 38%; MH3924A: 33% and HaCaT-RT3: 37% decrease). In a therapy study of HSVtkexpressing tumors with GCV, we achieved total tumor remission.
A promising strategy for the treatment of cancer is to render tumor cells susceptible to nontoxic chemotherapeutic agents using suicide genes, such as the herpes simplex thymidine kinase (HSVtk) gene. 1, 2 To obtain clinical utility, the suicide gene must be delivered to tumor cells in vivo while avoiding an undesired expression in normal tissues. 3 This can be achieved with a specific promoter directing the expression of a heterologous gene to the cells of interest. The expression of therapeutic genes under the control of a tissue-specific promoter has been reported by various groups. [4] [5] [6] [7] [8] [9] For a broader targeting of cancer cells, a tumor-specific promoter is of great interest, as cancer cells may lose their tissue-specific characteristics due to genetic instability. Therefore, a tumor-specific promoter is not restricted to a single tissue, but can be expressed in different types of cancer tissue or in highly dedifferentiated tumor cells. The hTERT (telomerase reverse transcriptase) promoter is active in virtually all types of tumors and immortal cells, but is silent in most adult somatic tissues. 10 The b-cateninresponsive promoter (CTP1) shows activity in colorectal metastasis, but not in normal tissue. 11 It is known that tumor cells have a higher glucose metabolism compared to normal tissue cells and tumorrelated changes in the expression of glycolysis-associated genes have been reported by several investigators. 12 Especially, the type 1 glucose transporter (GLUT1) gene is one of the early genes that are activated after transformation of cells with oncogenes such as src, ras or fps. [13] [14] [15] [16] [17] [18] [19] [20] An increase of GLUT1 mRNA was found 4-6 h after induction of the p21 c-H-ras oncoprotein, whereas morphologic changes occurred 72-96 h later. 18, 21 The facilitative glucose transporter GLUT1 has also been shown to be upregulated in human tumor tissues. 22, 23 Besides its expression in tumor cells, GLUT1 is also highly expressed in erythrocytes, brain tissue and embryonic tissue. 24 These tissues have no nucleus with DNA (erythrocytes) or no cell-dividing activity (erythrocytes, brain), which excludes them from being potential targets for the activity of suicide genes as HSVtk under the control of the GLUT1 regulatory elements in cancer therapy, and embryonic tissues are not a problem in cancer patients. In mice, the GLUT1 promoter sequence was mapped at À1.3 kb to þ 137 bp and two enhancer elements (enhancer 1 (SBb) at À3.3 to À2.7 kb and enhancer 2 (Bxb) at þ 16.7 to þ 18 kb) were characterized. The GLUT1 promoter sequence contains the following transcription control elements: a TATAA box, a CCAAT box, a potential AP2-binding site, a 12-Otetradecanoylphorbol-13-acetate-responsive element and two GC boxes. 25, 26 For the transfer of therapeutic genes efficient and safe vectors are needed. The human adeno-associated virus (AAV) is a very promising gene transfer agent for human gene therapy: AAV is an integrating vector with the potential for persistent expression following integration in the host genome in the absence of a helper virus. 27, 28 The vector efficiently transduces a wide range of host cells, and infection does not require host cell proliferation. It is also thought that the virus might be less immunogenic, due to the fact that it does not appear to transduce antigenpresenting dendtritic cells. In clinical trials, for example, for cystic fibrosis, rAAV2 vectors are in use for the transfer of the cystic fibrosis transmembrane conductance regulator gene to the airway. 29 Owing to the broad infection range of rAAV, no targeting of suicide gene expression can be achieved unless a specific promoter/ enhancer system is used. Therefore, the use of a regulatory element for a tumor cell-restricted gene expression with limited toxicity for benign tissues is necessary.
To investigate the role of the GLUT1 regulatory elements in tumor-specific gene expression, recombinant AAV vectors (AAV2) with the enhanced green fluorescence protein (EGFP) or the HSVtk gene under the control of the GLUT1 promoter and/or enhancer were used to transduce different tumor cells, a ras-transformed nontumor cell line, the spontaneously immortalized human keratinocyte cell line HaCaT and human umbilical vein endothelial cells (HUVECs). 30, 31 We present evidence that the suicide gene expression is restricted to tumor cells, if regulated by the GLUT1 promoter alone or together with the enhancer 1 fragment. Furthermore, the activity of the promoter in vivo is demonstrated.
Materials and methods

Cell culture
293T cells (human embryonic kidney cell line, transformed by the SV40 large T antigen), HaCaT (spontaneously immortalized human keratinocytes), HaCaT30ras A5/16 RT3 clone A (HaCaT-RT3) (ras-transformed HaCaT cells with a malignant phenotype, both obtained from Professor Dr N Fusenig, German Cancer Research Center, Heidelberg, Germany 32 ) and HeLaRC32 cells (a derivative of HeLa cell containing AAV-2 rep and cap genes 33 ) were maintained in Dulbecco's modified Eagles' medium containing 10% (vol/vol) heat-inactivated fetal calf serum (FCS). HCT116 (human colon carcinoma cell line) and Jurkat cells (human T-cell lymphoma) were cultured in RPMI-1640 containing 10% FCS; MH3924A cells (rat Morris hepatoma cell line) were cultured in RPMI-1640 containing 20% (vol/vol) FCS. HUVECs were cultured in Medium 199, Mod Earle's salts containing 20% FCS (vol/vol) and human epidermal growth factor. All cells were supplemented with 100 IU/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine (Invitrogen, Germany) and maintained at 371C and 5% CO 2 . All cell culture experiments were performed in triplicate and repeated at least twice. Construction of rAAV shuttle plasmid, production of rAAV particles and generation of recombinant cell lines
Chemicals
For gene transfer rAAV vectors were constructed. Both rAAV/cytomegalovirus (CMV)HSVtk and rAAV/ CMVEGFP plasmids were a derivative of pTRUF2 with the genes under the control of the human CMV major immediate-early promoter/enhancer. 34 The rAAV/GTI-1.3HSVtk (1345 bp GLUT1 promoter, obtained from Murakami et al 26 ) and rAAV/SBbGTI-1.3HSVtk (GLUT1 promoter and enhancer 1) were derived from rAAV/CMVHSVtk by replacing the CMV regulatory fragment with the promoter/enhancer fragment from the GLUT1 gene. The rAAV particles were generated as described by Grimm et al. 35 The purification and concentration of the virus was carried out by affinity chromatography using a cellulose sulfate column (Millipore, UK) and by ultracentrifugation (47,400 rpm, 2 hours 40 minutes). Finally, the purified particles were resuspended in 2 ml Optimem I medium (Invitrogen, Germany) and stored at À801C. The virus titers were determined according to the 'replicative titer' assay or fluorescent assay. 35 To establish Morris hepatoma cell lines for the stable expression of the HSVtk gene under control of GTI-1.3, a bicistronic rAAV vector based on the pTRUF2 expression vector was constructed: the HSVtk gene, the hygromycin resistance gene and an internal ribosomal entry site from the encephalomyocarditis virus between the genes to ensure simultaneous expression were taken from pGT60hTRAIL (Invivogen, USA) and cloned downstream of the glucose transporter 1 promoter (GTI-1.3) derived from the GTI-1.3CAT vector (obtained from Murakami et al 26 ) . rAAV particles were produced and MH3924A cells were infected with the viral particles with an MOI of 20 in Optimem I medium for 24 hour. The cells were then incubated in culture medium containing 425 g/ml hygromycin for 3 weeks until resistant cell lines were established.
Flow cytometry
To detect the egfp-reporter gene expression under the control of the different promoters, flow cytometry was I-deoxycytidine uptake assay
The HSVtk activity was evaluated by the uptake of specific substrates such as 3 H-GCV or 125 I-deoxycytidine as described by Haberkorn et al 32, 36 and Bi et al. 37 After seeding the cells in six-well plates, they were infected with rAAV at an MOI of 20 in Optimem I medium for 6 hour and incubated in culture medium for 48 hour. Thereafter, the cells were pulsed with 185 kBq 3 H-GCV/ml (or 37 kBq 125 I-deoxycytidine/ml) for 6 h. Cell lysis was carried out after washing twice with PBS in 0.3 N sodium hydroxide (NaOH). The intracellular radioactivity was counted in an LSC TRICARB 2500 TR scintillation counter (Canberra Packard, USA) and normalized to Bq/10 5 cells. To determine the 125 I-deoxycytidine uptake in relation to the incubation time, the recombinant cell line MHGTI-1.3hHSVtk and wild-type MH3924A cells were cultured with 185 kBq 125 I-deoxycytidine for 5, 10 and 30 min or 1, 3, 6 and 24 hour. Washing and counting was performed as described.
Growth inhibition of cells by GCV treatment
The cytotoxic effect of GCV on cells infected with rAAV containing the HSVtk gene was evaluated by determination of the cell growth inhibition after 48 h drug exposure. Cells were seeded in 24-well plates with a density of three Â 10 3 cells/well. After incubation for 72 h, they were infected with rAAV (MOI of 20) for 6 h in Optimem I medium. After medium replacement, the cells were incubated for further 48 h. For treatment, the cells were then exposed to 12.5 mM GCV for 48 h and the viable cell number was determined by a Coulter counter (Beckman Coulter, Germany).
Statistical procedures were performed with the SIG-MASTAT program (Jandel Scientific, Germany). Statistical significance was determined by the t-test. A Po.05 was chosen for statistical significance.
H-thymidine incorporation assay
To assess the GCV-induced inhibition of DNA synthesis, the incorporation of 3 H-thymidine (TdR) into DNA was measured in treated and untreated cells. The cells were seeded in six-well plates and infected with rAAV at an MOI of 20. After incubation for 48 h, the cells were treated with 12.5 mM GCV and incubated for 2 h. Then, the cells were pulsed in the presence of GCV with 185 kBq 3 H-TdR/ml and harvested 4 h later in ice-cold 0.5 M perchloric acid (PCA) after washing twice with PBS. The lysate was incubated for 30 min on ice and centrifuged at 1500 g. Thereafter, the pellet was washed with PCA, centrifuged again and dissolved in lysis buffer (0.3 M NaOH, 0.1% SDS). The radioactivity in the acid-soluble (supernatant) and acid-insoluble fraction (pellet, representing the fraction of 3 H-TdR incorporated into nucleic acids) was counted and normalized to Bq/10 5 cells.
Measurement of 131 I-deoxycytidine uptake in tumor tissue of rats
The experiments were performed in compliance with German laws relating to the conduct of animal experimentation. Eight Â 10 6 tumor cells were transplanted subcutaneously into the right GTI-1.3hNIS43 or four Â 10 6 wild-type MH3924A cells were transplanted into the left thigh of male ACI rats weighting 200-250 g. For distribution studies, only animals bearing tumors with a minimum size of 10 mm diameters were accepted. After injection of 200 ml of 131 I-deoxycytidine in 0.9% NaCl (14.8-18.5 MBq) into the lateral tail vein of the rats, the absolute amount of radioactivity (% injected dose/g wet tissue) was determined in 12 animals that were killed 6, 24 and 48 h postinjection by analyzing the organs using an LSC TRICARB 2500 TR scintillation counter (Canberra Packard, USA).
GCV therapy of HSVtk-expressing tumors of rats
The experiments were performed in compliance with the current version of the German Law on the Protection of Animals. Eight Â 10 6 MHGTI-1.3hNIS43 cells were transplanted subcutaneously into the right thigh or four Â 10 6 wild-type MH3924A cells into the left thigh of four adult male ACI rats weighing between 280 and 300 g. When the tumors reached a minimum size of 10 mm diameter, GCV treatment was started and rats received 150 mg/kg GCV by intraperitoneal injection until the HSVtk-expressing tumors showed total remission. Tumor volumes were calculated according to the formula
Results
Expression of the egfp-reporter gene under control of the GLUT1 regulatory element can be detected in tumor cells, but not in normal somatic cells
To demonstrate tumor-specific gene expression under the control of the GLUT1 regulatory element, the activity of the egfp-reporter gene was measured in tumor cells (HCT116, MH3924A and Jurkat), oncogene-transformed cells (HaCaT-RT3) and normal somatic cells (HaCaT and HUVEC). The CMV promoter was used as a nonspecific control (rAAV/CMVegfp) in comparison to Tumor-specific gene expression using GLUT1 S Sieger et al the tumor-specific expression of the GLUT1 regulatory element (rAAV/GTI-1.3egfp). FACS analysis was performed at 48 h after transient infection with rAAV/ CMVegfp viral particles and revealed fluorescence in all cell lines tested. EGFP expression under the control of the GLUT1 promoter element (rAAV/GTI-1.3egfp) was limited to the tumor cells and oncogene-transformed cells: 62% of the HCT116 cells, 47% of MH3924A, 167% of Jurkat and 71% of HaCaT30ras A5/16 RT3 cells expressed fluorescence in comparison to cells expressing egfp under the control of CMV (set to 100%) (Fig 1a-d) . Nontumor cell lines expressed only weak fluorescence after infection with rAAv/GTI-1.3egfp: HaCaT 8% and HUVEC 15% (Fig 1e and f) .
Activity of the HSVtk gene leads to enhanced uptake of the specific substrate GCV in tumor cells
In order to determine the HSVtk suicide gene activity under the control of the GLUT1 promoter constructs, a 3 H-GCV uptake assay was performed. Since phosphorylated GCV is trapped inside the cells due to its negative charge, the amount of accumulated 3 H-GCV indicates the enzyme activity obtained after HSVtk gene transfer. 32, 37 After infection with the rAAV/CMVHSVtk particles, all cell lines tested accumulated 3 H-GCV (HCT116: 1698%; MH3924A 151%; HaCaT-RT3: 183% and HaCaT: 292%; HUVEC: 352% increase compared to the untreated control) (Fig 2a-e) . After infection with rAAV/GTI-1.3HSVtk or rAAV/SBbGTI-1.3HSVtk particles, the increase of 3 H-GCV uptake was limited to tumor cells. We observed in HCT116 cells a 111% increase after infection with rAAV/GTI-1.3HSVtk, and 86% after infection with rAAV/SBbGTI-1.3HSVtk. In MH3924A cells, we observed a 130% increase of 3 H-GCV accumulation after infection with rAAV/GTI-1.3HSVtk, and a 35% increase after infection with rAAV/SBbGTI-1.3HSVtk. In HaCaT-RT3 cells, an increase of 257 and 300% was observed (Fig 2a-c) . No enhancement of 3 H-GCV uptake was seen in HaCaT cells (66% and 58% decrease). In HUVEC cells, no difference in 3 H-GCV uptake was measurable after infection with rAAV/GTI-1.3HSVtk (2% decrease), but a slight accumulation of 3 H-GCV occurred after infection with rAAV/SBbGTI-1.3HSVtk (25% increase) (Fig 2d and e) . (Fig 3a-e) . In contrast, infection with rAAV/GTI-1.3HSVtk particles and subsequent addition of GCV significantly reduced the number of tumor cells and Tumor-specific gene expression using GLUT1 S Sieger et al oncogene-transformed cells when compared to untreated cells (HCT116: 71%; MH3924A: 43% and HaCaT-RT3: 31% inhibition) (Fig 3a-c) , whereas the HaCaT cells continued to proliferate (6% growth inhibition, Fig 3d) . H-GCV uptake in cells after infection with recombinant AAV particles. HCT116 (a), MH3924A (b), HaCaT-RT3 (c), HaCaT (d) and HUVEC (e) cells were infected with rAAV/CMVHSVtk, rAAVGTI-1.3HSVtk or rAAV/SBbGTI-1.3HSVtk and incubated 2 days later with 3 H-GCV for 6 h. As the uptake of GCV is dependent on the activity of HSVtk, 3 H-GCV incorporation can be achieved in tumor cells by the GLUT1 promoter-driven HSV thymidine kinase, but not or only weak in normal cells. Data are mean values n ¼ 37SD.
Tumor-specific gene expression using GLUT1 S Sieger et al decrease in cell number either (2% growth inhibition, Fig 3e) . Following infection with the rAAV/SBbGTI-1.3HSVtk viral particles, no enhancement of the cytotoxic effect compared to the use of the GTI-1.3 promoter alone was achieved after GCV treatment (HCT116: 33%; MH3924A: 21% and HaCaT-RT3: 14% decrease of the cell number) (Fig 3a-c) . After infection with rAAV/ SBbGTI-1.3HSVtk, we observed a slight decrease of cell number in HaCaT of À4% and in HUVEC cells of À4% (Fig 3d and e) . H-thymidine incorporation into the DNA. In cells infected with rAAV/CMVHSVtk, we observed a decrease of DNA synthesis in all cell types tested. HCT116 showed 59% less incorporation of 3 HTdR into the DNA compared to cells without GCV treatment. MH3924A showed 76%, HaCaT-RT3 45%, HaCaT 41% and HUVEC 62% decrease in the 3 H-TdR incorporation into the DNA (Fig 4a-e) , whereas a decrease of 3 H-TdR incorporation into DNA after infection with rAAV/GTI-1.3HSVtk viral particles occurred exclusively in MH3924A (À33%), HCT116 (À38%) and HaCaT-RT3 (À37%) cells (Fig 4a-c) . After infection with rAAV/SBbGTI-1.3HSVtk and subsequent addition of GCV, we achieved a decrease in 3 H-TdR incorporation of 18% in HCT116 cells, 40% in MH3924A and 35% in HaCaT-RT3 cells (Fig 4a-c) . In contrast to the tumor cell lines, HaCaT and HUVEC cells infected with rAAV/GTI-1.3HSVtk or rAAV/SBbGTI-1.3HSVtk do not show a significant change in 3 H-TdR incorporation into DNA when treated with GCV. HaCaT cells even expressed an increase of 3 H-TdR incorporation into DNA after infection with rAAV/GTI-1.3HSVtk (20% increase) and rAAV/SBbGTI-1.3HSVtk (17% increase). For HUVEC cells, we observed an 8% increase after rAAV/GTI-1.3HSVtk infection and 8% decrease after infection with rAAV/SBbGTI-1.3HSVtk as compared to untreated cells (Fig 4d and e) .
I-deoxycytidine uptake is enhanced in stable recombinant cell lines
After infection of MH3924A cells with rAAV/GTI-1.3HSVtkIREShph and selection with hygromycin, resistant cell lines were established. In order to investigate the enzyme activity of the HSVtk gene product in the recombinant MH3924A cell lines, the time-dependent uptake of the HSVtk substrate 125 I-deoxycytidine was measured over 24 h. In the genetically modified cells, MHGTI-1.3HSVtk4, we reached a 56-fold higher accumulation of 125 I-deoxycytidine, whereas no accumulation was detectable in wild-type MH3924A cells (Fig 5) .
I-deoxycytidine uptake is increased in HSVtk-expressing hepatoma in vivo
To investigate the activity of the HSVtk gene under control of the GLUT1 promoter in Morris hepatoma in vivo, MHGTI-1.3HSVtk4 cells or wild-type MH3924A cells were transplanted into the right and left thigh of male young adult ACI rats. After the animals had been injected with 131 I-deoxycytidine, scintigraphic images were obtained to evaluate radioactivity in the tumor tissue and different organs. The HSVtk-expressing tumors accumulated two-fold more 131 I-deoxycytidine than the wild-type hepatoma, leading to weak scintigraphic visualization of the modified tumor until 48 h after tracer administration. Table 1 presents the ex vivo quantification of the 131 I-deoxycytidine uptake per gram of tissue from tumors and various organs 6, 24 and 48 h after tracer administration. The uptake in HSVtk-expressing tumors was higher than the accumulation in wild-type tumors, as well as in the blood and in most benign tissues.
GCV therapy induces regression of genetically modified Morris hepatoma in rats
Treatment of animals bearing HSVtk-expressing and wild-type tumors with GCV was performed to compare the therapeutic effects on HSVtk-expressing tumors and unmodified tumors. MHGTI-1.3HSVtk4 cells or wildtype MH3924A cells were transplanted into the right and left thigh of male young adult ACI rats. For therapy, the animals received daily i.p. injections of 150 mg GCV/kg body weight and the tumor size was determined. After 12 days of GCV treatment, a total remission of the HSVtkexpressing tumors occurred, while the wild-type tumors remained unaffected to GCV treatment and a 71% increase of the tumor volume was observed (Fig 6) .
Discussion
In the present study, GLUT1 regulatory sequences were employed for tumor-enhanced expression of the EGFP and HSVtk genes in tumor cell lines and an oncogenetransformed cell line. FACS analysis of different tumor cell lines, oncogene-transformed cells and normal somatic cells after transient infection with recombinant viral particles bearing the egfp gene under control of the GLUT1 promoter revealed an elevated fluorescence only in the tumor cell lines (HCT116, MH3924A and Jurkat) and the oncogene-transformed cells (HaCaT-RT3). However, the intensity of fluorescence achieved after infection with rAAV particles containing the GLUT1 regulatory element could not reach the fluorescence achieved by the CMV promoter, which is interpreted as a weaker promoter activity for GLUT1 as compared to CMV.
The accumulation of 3 H-labeled GCV, a specific substrate for the HSV thymidine kinase, in rAAV/GTI-1.3HSVtk-infected tumor cells is a marker for the enhanced expression of the HSVtk gene controlled by the GLUT1 promoter in tumor cells. Tumor cells and HaCaT-RT3 cells showed increased accumulation of 3 H-GCV, whereas no visible accumulation occurred in nontumor cells. The differences in the amounts of GCV accumulated in the different cell lines, whether infected or noninfected, can be explained by variations in the affinity and transport capacity for GCV between these cell lines. These effects might also explain the drop of accumulated 3 H-GCV for HaCaT cells infected with rAAV/GTI-1.3HSVtk compared to the noninfected control cells (Fig 2c) . Infection with rAAV particles carrying the HSVtk gene under the control of the GLUT1 promoter led to efficient tumor cell growth inhibition after exposure to GCV. When the tumor-and ras-transformed cell lines were infected with rAAV bearing the GLUT1 promoter, the decrease of cell number after GCV treatment was similar to that achieved after infection with rAAV/CMVHSVtk. GCV exposure also resulted in a reduction of 3 H-TdR uptake into the acid-insoluble fraction (representing nucleic acids such as DNA), whereas no effect of GCV was seen in nontumor cells. The in vitro data provide slight variations between the activity of the suicide gene or the reporter gene. As stated above, differences in gene expression can mainly be explained by variations in the infection efficiency of the virus particles. Furthermore, variations in the transport of GCV into the cell and the following intracellular metabolism may be responsible for differences between the decrease of cell number after GCV treatment (here also, the bystander effect might play a critical role in the effect of GCV treatment on the decrease of cell number), thymidine incorporation in the presence of GCV or accumulation of tritium-labeled GCV within the same cell line. Nevertheless, the introduction of the EGFP and the HSVtk gene under the control of the GLUT1 promoter into tumor and immortalized normal cells resulted in a pattern of transgene expression that was strongly enhanced in tumor cells. Previously characterized tissue-specific promoters are generally active only in the type of cancer from which they are derived. [4] [5] [6] In contrast, the GLUT1 promoter is active in tumors of different origin, which indicates that this promoter may be applied for gene therapy in a wider range of human malignancies. Besides the achieved tumor selectivity, the GLUT1 promoter shows a much stronger activity than most tissue-specific promoters described in the literature, which mostly reach only weak transcriptional activity, even when enhancer elements are used. 5, 6 To further enhance the activity of the GLUT1 promoter, we designed constructs that contain one of the two enhancer elements. 26 However, we could not observe a higher activity of the transfected gene when the promoter is combined with the enhancer element (enhancer 1 SBb; Fig 2) . These findings are not consistent with data obtained from the literature, where an eight-fold 125 I-deoxycytidine uptake by MHGTI-1.3HSVtk4 increased permanently over 24 h, whereas uptake by MH wt remained low. Data are mean values n ¼ 37SD. Tumor-specific gene expression using GLUT1 S Sieger et al activation for enhancer 1 is described. 26 These differences in enhancer activity may be due to the different cell lines used for the transduction experiments. Furthermore, the results obtained from the uptake experiments with thymidine and GCV in HaCaT and HUVEC cells favor the possibility that the decrease in cell number in cells infected with rAAV/SBbGTI-1.3HSVtk and treated with GCV is caused by unspecific activating elements in the enhancer.
We also investigated whether the transduction of the HSVtk gene under control of the GLUT1 promoter element is sufficient to induce 131 I-deoxycytidine uptake in Morris hepatoma (MH3924A) cells and tumor tissue in rats to obtain a diagnostic tool for the assessment of HSVtk activity. Therefore, we established the genetically modified Morris hepatoma cell line MHGTI-1.3HSVtk4 and evaluated its HSVtk enzyme activity by uptake studies and therapy experiments. In the HSVtk-expressing tumor, the uptake was two-fold higher as compared to the wild-type tumor (compared to a 54-fold accumulation in vitro) followed by a decrease of radioactivity in both tumors and all organs for the next 48 h. However, at 48 hour p.i., the radioactivity in the HSVtk-expressing tumor was three-fold higher than in the wild-type tumor and also higher than in most benign tissues.
The difference in tracer accumulation between the in vitro and the in vivo study may be due to the chemical instability of 131 I-deoxycytidine, which could lead to dehalogenation of the compound. Chemical instability might therefore lead to an accumulation of deoxycytidine in the HSVtk-expressing tumor, but the radioactive label may be lost in a substantial fraction leading to a low signal. Another explanation may be rapid clearance of the tracer out of the body as well as competition for the transport systems by natural nucleosides in the serum. Especially in rats and mice, a 10-fold higher thymidine concentration in the serum as compared to humans has been observed. 38 Since treatment of the animals with GCV caused complete remission of HSVtk-expressing tumors within 12 days with no response in wild-type tumors, we expect that HSVtk activity is present in the tumors. Although a complete remission of the transformed tumor occurred, weight loss of the rats was observed as a side effect, as other cell populations with a high cell division frequency such as bone marrow are affected by GCV. This effect has been observed in former in vivo experiments. 39 In conclusion, the in vitro and in vivo assays performed so far indicate that the GLUT1 promoter shows high activity in tumor cells and no significant activity in nontumor cells. When GLUT1 is used as the regulatory element for HSVtk, a cytotoxic effect after GCV treatment is restricted to tumor tissue, a fact that makes GLUT1 a promising regulatory element for use in a tumor-specific gene therapy. Since the GLUT1 promoter is not restricted to one single tissue, it has the advantage to be activated in a variety of tumor cells that have lost their tissue-specific characteristics. Therefore, the GLUT1 promoter sequence offers great potential as a tumorspecific promoter in gene therapy.
